Malignant Bone Marrow Neoplasm

A 60 year old female relapsed or refractory AML patient, white, and 55.2 kg, with favorable cytogenetic risk status Inv(16), and blast percentage of 95, had D835Y at time of bone marrow screening. Var… (full text at CIViC)

PMID 32040554 · Tarver et al., 2020 · Open in CIViC

A 35 year-old male patient (AML4) presented with a FLT3-ITD mutation at diagnosis and was refractory to induction and salvage chemotherapy. He then received quizartinib and underwent allogenic transpl… (full text at CIViC)

PMID 27908881 · Lee et al., 2017 · Open in CIViC

Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

A patient (29/M) had 2 weeks with oral cavity ulcer and nasal bleeding and was diagnosed with AML with marrow including 91.5 % blasts with morphologic features of AML-M5. Karyotype was abnormal (47, … (full text at CIViC)

PMID 27408351 · Yue et al., 2016 · Open in CIViC

Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

Ba/F3 cells expressing FLT3 D835Y and treated with sorafenib demonstrated a dose-dependent inhibition of cell proliferation. Ba/F3 cells transformed with FLT3 D835Y showed a 50% inhibition of cell pro… (full text at CIViC)

PMID 17229632 · Lierman et al., 2007 · Open in CIViC

MLN518 inhibited the proliferation of Ba/F3 cells transduced with FLT3 activation loop mutation D835Y (IC50 > 10 micromolar). In addition, MLN518 inhibited phosphorylation of FLT3, STAT5 and ERK. Trea… (full text at CIViC)

PMID 15256420 · Clark et al., 2004 · Open in CIViC

Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD or FLT3-ITD/F691L. Proliferation and biochemical studies showed that the FLT3-ITD D839A (IC50 = 4.0μM) and FL… (full text at CIViC)

PMID 25847190 · Smith et al., 2015 · Open in CIViC

This is a case report about an adult patient with acute promyelocytic leukemia (APL) who had relapse in a testicle prior to systemic relapse of APL. Retrospective analysis of the preserved samples fro… (full text at CIViC)

PMID 23816818 · Zou et al., 2013 · Open in CIViC

Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC)

PMID 15667533 · Smith et al., 2005 · Open in CIViC

Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD. Proliferation studies showed that the FLT3-ITD D839H (IC50 = 8.6μM) confers relative resistance to PLX3397 i… (full text at CIViC)

PMID 25847190 · Smith et al., 2015 · Open in CIViC

Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD or FLT3-ITD/F691L. Proliferation and biochemical studies showed that the FLT3-ITD D839N (IC50 = 0.85μM) and F… (full text at CIViC)

PMID 25847190 · Smith et al., 2015 · Open in CIViC

The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC)

PMID 27099147 · Uras et al., 2016 · Open in CIViC

In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC)

PMID 15459012 · Fiedler et al., 2005 · Open in CIViC

In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC)

PMID 27099147 · Uras et al., 2016 · Open in CIViC

In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC)

PMID 15459012 · Fiedler et al., 2005 · Open in CIViC

FLT3 F691L was observed in 2 patient samples collected after at least 28 days of treatment with crenolanib. Prior to treatment with crenolanib, both patients were treated with quizartinib. Ba/F3 cells… (full text at CIViC)

PMID 30651561 · Zhang et al., 2019 · Open in CIViC

A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC)

PMID 22858906 · Williams et al., 2013 · Open in CIViC

Constructs of Ba/F3 cell line containing the FLT3 open reading frame with an internal tandem duplication of (FLT3-ITD) were used to induce point mutations in the ATP binding pocket of FLT3. Constructs… (full text at CIViC)

PMID 15374944 · Cools et al., 2004 · Open in CIViC

Gilteritinib is the first FLT3 inhibitor approved by the Food and Drug administration (FDA) as monotherapy in adult refractory/relapse acute myeloid leukemia (R/R AML) patients with FLT3-ITD and/or ty… (full text at CIViC)

PMID 32040554 · Tarver et al., 2020 · Open in CIViC

Using in vitro proliferation assay in Ba/F3 cells, it was found that the cells with FLT3-ITD G697S exhibited potent resistance to Gilteritinib. Similar resistance was found in cells bearing FLT3-ITD F… (full text at CIViC)

PMID 32040554 · Tarver et al., 2020 · Open in CIViC

The variant was identified by NGS in a CML (unmatched analysis) (Supplementary File 2).

PMID 32943879 · Wu et al., 2020 · Open in CIViC

In this study, activating FLT3 mutations identified in patients with Acute Myeloid Leukemia were modeled using Ba/F3 cell lines generated by site-directed mutagenesis and transfection. These cells wer… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

In this study, FLT3 activating mutations identified in patients with acute myeloid leukemia were modeled using murine Ba/F3 cells generated by site-directed mutagenesis and transfection. These cells w… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.

PMID 24801015 · Port et al., 2014 · Open in CIViC

In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.

PMID 21067377 · Ley et al., 2010 · Open in CIViC